Can Borrelia IgM alone diagnose active infection?

Borrelia IgM is an early, but inherently context-dependent, serologic signal. For an 83-year-old man—as for other adults—its clinical meaning rests on symptom pattern, onset, exposure likelihood, and validated confirmatory testing rather than on the IgM result itself.

Clinical interpretation

• IgM can support a recent Borrelia-directed immune response during a compatible illness of ≤30 days, when it typically precedes IgG. It does not establish generic recent immune activation, current infection, or that Borrelia is causing current symptoms.
• CDC-aligned guidance limits clinical use of isolated IgM to the first 30 days after symptom onset. With longer illness duration, IgG—not isolated IgM—should guide interpretation.
• Two-tier serology is required: an initial EIA/IFA followed by immunoblot or validated second EIA. A positive antibody result indicates immune exposure, not necessarily active disease.

False positivity and persistence

• Cross-reactive Borrelia IgM is documented with EBV/mononucleosis, CMV and other viral infections, syphilis, relapsing-fever Borrelia, rheumatoid factor, and autoimmune disease.
• False-positive IgM findings are clinically consequential: retrospective cohorts classified 53.3% and 27.5% of positive Lyme IgM immunoblots as false positive, particularly with atypical symptoms, absent exposure, or illness >30 days with negative IgG.
• IgM can remain detectable after resolved, treated infection. About 10% of treated erythema-migrans patients remained IgM-reactive at one year, and persistence has been documented for years; this is not evidence of treatment failure or ongoing infection.

Bottom line

• Borrelia IgM is supportive evidence only in an appropriately timed, clinically compatible presentation. Without that context—especially after 30 days or with negative IgG—it can reflect cross-reactivity or persistent antibodies and should not independently diagnose active infection.